Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration

Kim, Ramasamy
November 2007
Indian Journal of Ophthalmology;Nov2007, Vol. 55 Issue 6, p413
Academic Journal
journal article
Recent developments may provide an opportunity to improve outcome in individuals who develop neovascular age-related macular degeneration (ARMD). Several therapies have been introduced that show promise for halting the progression of this disorder. However, data from controlled clinical trials to test the relative efficacy of different management strategies across the subtypes of disease remain limited. New treatment modalities that target the neovascularization process, including leakage from choroidal neovascularization (CNV), are currently being developed. Vascular endothelial growth factor (VEGF) has been implicated as a key mediator in the pathogenesis of ARMD-related CNV. Anti-VEGF strategies show promise as potential therapeutic agents for the treatment of CNV and are currently undergoing active clinical investigation. Such strategies include anti-VEGF antibodies, anti-VEGF aptamer, gene therapy and protein kinase C inhibition. This article reviews the mechanism of action and rationale for anti-VEGF drugs in ARMD.


Related Articles

  • Comparison studies of anti-VEGF agents a 'global effort'. Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p25 

    The article reports on the presentation by doctor Daniel F. Martin on the comparison studies and international effort to understand the differences between the two anti-vascular endothelial growth factor (VEGF) agents, ranibizumab and bevacizumab.

  • IN THE JOURNALS. Hasson, Matt // Ocular Surgery News;6/25/2014, Vol. 32 Issue 12, p22 

    This section offers news briefs on ophthalmology. No distinct advantage was exhibited by corneal debridement in treating corneal lesions and microsporidial keratoconjunctivitis. A study shows that large-angle infantile esotropia have been reduced by three-muscle surgery. A study shows that a...

  • New anti-VEGF shows good results in poor responders to previous anti-VEGF therapy.  // Ocular Surgery News;7/25/2013, Vol. 31 Issue 14, p14 

    The article focuses on the therapeutic use and efficacy of aflibercept, an anti-vascular endothelial growth factor (VEGF) drug, compared to other anti-VEGF therapy, discussed by ophthalmologist Stephan Michels during the 2013 European Society of Ophthalmology meeting in Copenhagen, Denmark.

  • Vision improves in anti-VEGF veterans enrolled in HiPED study.  // Ocular Surgery News;9/25/2012, Vol. 30 Issue 18, Special section p10 

    The article reports that anti-vascular endothelial growth factor veterans with wet age-related macular degeneration and pigment epithelial detachments achieved better visual acuity after receiving monthly injections of ranibizumab, according to Anne Fung who presented the results of the High...

  • Good early results seen with anti-VEGF refillable port delivery system. Biro, Ashley // Ocular Surgery News;1/25/2013, Vol. 31 Issue 2, p34 

    The article reports that early detection results wit age related macular generation are comparatively beneficial where the best outcomes are associated with monthly treatments.

  • Vitreomacular interface affects anti-VEGF injection intervals for AMD. Ahem, Steve; Hasson, Matt // Ocular Surgery News;4/25/2014, Vol. 32 Issue 8, p17 

    The article discusses a study which shows that anti-vascular endothelial growth factor (VEGF) injection intervals for the management of age-related macular degeneration is affected by vitreomacular interface disease.

  • Clinical practice, study protocols for treating AMD with anti-VEGF injections vary widely. Kronemyer, Bob // Ocular Surgery News;1/25/2015, Vol. 33 Issue 2, p18 

    The article discusses a study published in "Ophthalmic Surgery, Lasers and Imaging Retina" which states huge variation in frequency of anti-Vascular endothelial growth factor (VEGF) injections given to age-related macular degeneration (AMD) patients during clinical trial. Topics discussed...

  • Anti-VEGF patterns of use may vary for DME cases in clinical practice. Harrison, Laird // Ophthalmology Times;Sep2015, Vol. 40 Issue 15, p70 

    The article presents the results of a study on the effectiveness of anti-vascular endothelial growth factor (VEGF) treatments for diabetic macular edema conducted by Dr. Kevin Blinder at Washington University in St. Louis, Missouri. Topics mentioned include disappointing results in clinical...

  • Antiplatelet-derived growth factor with anti-VEGF shows promise for neovascular AMD.  // Ocular Surgery News;12/25/2012, Vol. 30 Issue 24, Special section p10 

    The article reports that an antiplatelet-derived growth factor combined with ranibizumab has shown promise in treatment of neovascular age-related macular degeneration.

  • Ranibizumab and the eye. Noble, Jason; Chaudhary, Varun // CMAJ: Canadian Medical Association Journal;4/19/2011, Vol. 183 Issue 7, p822 

    The article offers information on the use of the VEGF-A inhibitor ranibizumab as treatment for wet age-related macular degeneration. It states that several large randomized controlled trials have been conducted to examine the efficacy and safety of ranibizumab. It also says that systemic adverse...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics